QUESTCOR INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Questcor Pharmaceuticals Inc. (QCOR) Over the Proposed Sale of the Company to Mallinckrodt plc (MNK)
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Questcor Pharmaceuticals Inc. (“Questcor” or the “Company”) (Nasdaq: QCOR) for potential breaches of fiduciary duties in connection with the sale of the Company to Mallinckrodt plc for approximately $5.2 billion. The Company’s stockholders will receive $30.00 cash and 0.897 Mallinckrodt shares for each share of Questcor common stock they own.
The investigation focuses on whether Questcor’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair sales process and whether and by how much this proposed transaction undervalues the Company to the detriment of Questcor’s shareholders.
If you own common stock in Questcor and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at firstname.lastname@example.org or by telephone at (877) 247-4292 or (212) 983-9330.